Station 4L Lymph Node Dissection Versus No Dissection in Clinical Stage I Solid Nodule-Type Invasive NSCLC

This multicenter, prospective, randomized clinical trial will enroll adults aged 18 to 75 years with resectable clinical stage I (T1-T2aN0M0) invasive non-small cell lung cancer presenting as a single solid nodule (consolidation-to-tumor ratio 1.0) in the left lung. After intraoperative frozen-section confirmation of invasive non-small cell lung cancer and completion of standard lung resection and systematic mediastinal lymph node dissection, participants will be randomly assigned 1:1 either to undergo station 4L lymph node dissection or to omit station 4L dissection. The primary hypothesis is

Trial Details

NCT ID
NCT07801430
Phase
NA
Sponsor
Fudan University
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • Station 4L Lymph Node Dissection
Locations (sample)
  • Shanghai, Xuhui, China|31.22222,121.45806

Key Eligibility Criteria

  • Age 18 to 75 years.
  • A single solid pulmonary nodule (consolidation-to-tumor ratio of 1.0) located in the left lung.
  • Resectable clinical stage I (T1-T2aN0M0) non-small cell lung cancer, with a maximum tumor diameter of 4 cm or less, evaluated by positron emission …
  • Planned complete lung resection by segmentectomy or lobectomy with systematic mediastinal lymph node dissection.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →